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Vascular endothelial growth 
factor signaling requires glycine to 
promote angiogenesis
Dongqing Guo1, Colin E. Murdoch  2, Hao Xu3, Hui Shi3, Dayue Darrel Duan4, Asif Ahmed2 & 
Yuchun Gu3,5
Peripheral vascular occlusive disease (PVOD) is a common manifestation of atherosclerosis, and it 
has a high rate of morbidity. Therapeutic angiogenesis would re-establish blood perfusion and rescue 
ischemic tissue. Vascular endothelial growth factor (VEGF) induces angiogenesis and can potentially 
be used to treat ischemic diseases, yet in clinical trials VEGF has not fulfilled its full potential with 
side effects. Whether amino acids promote angiogenesis and the molecular mechanisms are largely 
unknown. Here we showed that (1) Glycine significantly promoted angiogenesis both in vitro and  
in vivo and effectively protected mitochondrial function. (2) Activation of glycine transporter 1(GlyT1) 
induced by VEGF led to an increase in intracellular glycine. (3) Glycine directly bounded to voltage 
dependent anion channel 1 (VDAC1) on the mitochondrial outer membrane and inhibited its opening. 
These original results highlight glycine as a necessary mediator in VEGF signalling via the GlyT1-
glycine-mTOR-VDAC1 axis pathway. Therefore, the findings in this study are of significance providing 
new mechanistic insights into angiogenesis and providing better understanding of glycine function in 
angiogenesis, which may provide valuable information for development of novel therapeutic targets for 
the treatment of angiogenic vascular disorders.
Peripheral vascular occlusive disease (PVOD) is a common manifestation of atherosclerosis, and it has a high 
rate of morbidity1. Sufficient collateral vessel formation can potentially re-establish blood perfusion and rescue 
ischemic tissue. Angiogenesis is the generation of new blood vessels from existing vasculature2, which is vital 
for reproduction, development, and tissue repair3. It is also a major pathological process of many angiogenic 
disorders such as malignancies4, diabetic retinopathy5, rheumatoid arthritis6, psoriasis7 and rosacea8. VEGF is a 
key regulator of angiogenesis9 and the only specific mitogen for endothelial cells10. A better understanding of the 
VEGF-mediated signaling pathways in endothelial cells will help determine the key molecular targets on angi-
ogenesis in the vasculature. To date, three key pathways in the VEGF signals have been reported which include 
Raf-MEK (mitogen-activated or extracellular signal-regulated protein kinase kinase)-MAPK (mitogen-activated 
protein kinase) pathway, PI3K (phosphatidylinositol 3-kinase)-Akt pathway, and Src-FAK (focal adhesion 
kinase) pathway11. Transcriptional coactivator PGC-1 alpha (peroxisome-proliferator-activated receptor-gamma 
coactivator-1 alpha), a potent metabolic sensor and regulator, is induced by a lack of nutrients and oxygen. PGC-1 
alpha powerfully regulates in vivo VEGF expression and angiogenesis in cultured muscle cells and skeletal mus-
cle12. To identify additional signals in the pathogenesis of human vascular disorders, a large-scale proteomic 
approach was applied to define the mammalian target of rapamycin complex 2 (mTORC2)-fork head box protein 
O1 (FoxO1) axis in VEGF signal and feedback activation of receptor tyrosine kinases13. In addition to stimulat-
ing endothelial cell proliferation and migration, VEGF is known to cause vasodilation and to increase vascular 
permeability14. All these actions contribute to the pathophysiological processes related to VEGF over-activity. So 
it is very important to find new and safe targets which modulate angiogenesis. Amino acids have been identified 
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as potential candidates in promoting survival15,16, but the effects of amino acids in the angiogenesis are still 
unknown.
Here we investigated the key mediators involved in VEGF signaling and found that glycine is required in the 
VEGF signaling pathways. Our data provide insights that glycine could promote the mitochondrial function by 
inhibiting VDAC1 opening.
Results
Glycine was required in the VEGF signals. VEGF promotes endothelial cell migration, proliferation, 
angiogenesis and entering of cell cycle. mTOR is a central regulator of cellular growth17. VEGF induces phospho-
rylation of the well characterised ribosomal S6 protein, while has no effect on mTOR expression. Removal of all 
amino acids in the cell medium also resulted in loss of VEGF-induced ECs proliferation with no change of the 
expression of P-S6 in response to VEGF (Fig. 1a). Taken together, these results suggested a unique role for amino 
acids in the mTOR signaling induced by VEGF.
To find out which amino acids involved in the VEGF signals, liquid chromatography-mass spectrometry 
(LC-MS) was used and revealed that glycine was higher in ECs cytoplasm induced by VEGF (Fig. 1b). Our results 
showed that exogenous glycine obviously elevated the level of P-S6 via the mTOR signaling pathway, but had no 
effect on S6 expression and other amino acids also have the same effects (Fig. 1c).
Glycine promoted the angiogenesis. Next we explored the role of glycine in vivo using the hindlimb 
ischemia model. During the hind limb ischemia surgery glycine was administered into the saphenous artery and 
immediately tied off prior to a 1.5 mm section being removed. The control mice were treated with same volume 
of saline. Continuous administration of glycine through dietary supplementation after ischemia was used to 
maintain glycine therapeutic effects during the two-week period. Glycine treatment enhanced neovascularization 
significantly promoting the recovery of vascular flow from the third day (Fig. 2a). Glycine promoted HUVECs to 
form networks in vitro (Fig. 2b). Using an in vivo assay, glycine alone promoted the angiogenesis on the chorioal-
lantoic membrane (Fig. 2c). During these assays, VEGF was used as positive control.
Glycine obviously promoted the mitochondrial function. We explored whether glycine regulated 
angiogenesis by affecting the mitochondrial functions. Interestingly, glycine induced increase of oxygen con-
sumption (OCR) coupled to FCCP (Fig. 3a). The mitochondrial activity also significantly increased with the 
stimulation of glycine (Fig. 3b). Intracellular ATP production increased for nearly 100% in glycine-induced ECs 
(Fig. 3c). Mitochondrial membrane potential (ΔΨm) is essential to maintain mitochondrial oxidative phospho-
rylation, produces the adenosine triphosphate and maintains the normal physiological function of cells18. When 
ECs cultured in the medium without amino acids, the ΔΨm increased significantly in contrast to the group 
with completed medium, while the group with supplement of glycine maintained the ΔΨm stability (Fig. 3d). 
Moreover, glycine alone decreased the intracellular ROS production (Fig. 3e) and promoted the nitric oxide 
production (Fig. 3f).
VEGF activated GlyT1 and glycine directly bound to VDAC1 on the mitochondria. Glycine con-
sumption and expression of the mitochondrial glycine biosynthetic pathway were strongly correlated with the 
proliferation rate of cancer cells19. Defects in glycine metabolism in the mitochondria as a result of reduction in 
mitochondrial serine hydroxymethyltransferase (SHMT2) and glycine C-acetyltransferase (GCAT) expression 
are partly responsible for the reduction in mitochondrial translation20. To explore the potential relevance of gly-
cine metabolism in VEGF signals, we examined the expression of the mitochondrial glycine synthesis enzyme 
SHMT2 and plasma glycine synthesis enzyme SHMT1 by the stimulation of VEGF21 and found that their expres-
sion had no change (Fig. 4a). Sarcosine, the inhibitor of glycine transporter (GlyT) could inhibit the proliferation 
induced by VEGF (Fig. 4b). There are two kinds of glycine transporters including GlyT1 and GlyT222. VEGF 
could promote the expression of GlyT1 (Fig. 4c). Knocking down the expression of GlyT1 using siRNA by elec-
troporation (Fig. 4d) and subsequently testing intracellular glycine using LC-MS. VEGF couldn’t increase the 
intracellular glycine with siGlyT1 treatment (Fig. 4e). Our results suggested that VEGF activated the glycine 
transporter 1 and increased the intracellular glycine. Incidentally, glycine significantly inhibited the VDAC-1 cur-
rents (Fig. 4f and g) as shown in single channel recordings where second messengers are not present; suggesting a 
novel pathway which glycine regulates mitochondria. Gd3+ is a recognized blocker for VDAC-1.
Discussion
Endothelial cells rely on glycolysis rather than via oxidative phosphorylation23. In the current study, VEGF 
enhanced mitochondrial function, including intracellular ATP production, oxidative respiration, ROS defense 
enzymes and nitric oxide. Enhanced mitochondrial function was mediated by activating mTOR signaling path-
way and the effects relied on the presence of glycine. By LC-MS, glycine showed increasing in intracellular pools 
by the stimulation of VEGF. Glycine (Gly) is the simplest non-essential amino acid, which participates in the 
synthesis of proteins and many physiologically important functions, including anti-inflammation24, immuno-
modulation25, cytoprotection26 and neurotransmitter27. Glycine has been showed to be related to the rapid cancer 
cell proliferation19 and could reverse the expression of aging phenotypes20. Administration of glycine indeed 
reduced mild ischemia-reperfusion injury in the kidney in vivo, in part by decreasing initial damage and prevent-
ing chronic hypoxia28. In our study, glycine could mimic the effects of VEGF on ECs to promote in vitro matrigel 
angiogenesis and in vivo angiogenesis, including chorioallantoic membrane and hind-limb ischemia. Glycine also 
effectively protected the mitochondrial functions of ECs. Single channel recordings revealed that glycine could 
directly bind to VDAC1 and inhibit the opening of VDAC1, which may interfere mitochondrial functions and 
angiogenesis. There are 3 subtypes of VDAC, but VDAC1 is highly expressed in human, which controls the transit 
of adenine nucleotides, Ca2+, and other metabolites both into and out of the mitochondria29. The channel may be 
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also a constituent of the mitochondrial permeability transition pore (PTP) and plays a major role in mitochondria 
mediated apoptosis30. Down regulation of VDAC-1 by siRNA prevents cisplatin induced Bax activation and cell 
death31. Molecular determinant for binding site of glycine on VDAC-1 is required further investigation. What’s 
Figure 1. Glycine was required in the VEGF signals. (a) HUVECs cultured in the medium with or without 
amino acids were treated with 20 ng/ml VEGF for 24 hours. Immunoblots of P-S6 and S6 were shown. 
Membranes were reprobed for ß-actin as loading control. Gray values were analyzed by the Image J software 
and presented in the graph (n = 3). (b) Intracellular content of alanine(Ala), arginine(Arg), asparagine(Asn), 
aspartic acid(Asp), cysteine(Cys), γ-aminobutyric acid(Gaba), glutamine(Gln), glutamic acid(Glu), 
glycine(Gly), histidine (His), isoleucine(Ile), leucine(Leu), lysine 37, methionine(Met), phenylalanine(Phe), 
proline(Pro), serine(Ser), threonine(Thr), tryptophan(Trp), tyrosine(Tyr) and valine(Val) in control and 20 ng/
ml VEGF-treated ECs for 24 h. LC-MS was used to detect relative intracellular quantities of amino acids in ECs 
in the absence and presence of VEGF (n = 3). (c) Immunoblot of total S6 and P-S6 in untreated and different 
amino acids-treated ECs. The concentration of amino acids: glycine(140 uM), leu(1.33 mM), tyro(1 mM), 
ala(1 mM), ser(1 mM). The treatment time was 5 h. Quantitative analysis was presented in the graph (n = 3).
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more, other amino acids also could promote the mitochondrial function in our results while they weren’t involved 
in the VEGF pathway. The effects of other amino acids need to be explored further.
In summary, our data provide evidence that VEGF stimulates endothelial cell migration, proliferation and 
angiogenesis via GlyT1-glycine-mTOR-VDAC1 axis. Our results suggest that glycine is required in VEGF sign-
aling by promoting mitochondrial function via VDAC1 inhibition, which may be of significance to provide new 
mechanistic insights for therapeutic exploitation. Further investigation of the function of glycine and GlyT1 in 
angiogenesis may represent novel therapeutic targets for the treatment of angiogenic vascular disorders.
Figure 2. Glycine could promote the angiogenesis. (a) Hind-limb ischemia was created in C57 mice through 
femoral artery ligation. Upper: Serial laser Doppler analysis of blood perfusion in hindlimbs of mice injected 
with saline, glycine or VEGF at the day 3, 7 and 14. The concentration: 140 uM glycine and 20 ng/ml VEGF. 
The volume: 100 ul. Down: Quantitative analysis of blood flow using percentage of the ischemic limb relative 
to the control limb (n = 6). Results represented mean ± SEM of n independent experiments. **P < 0.01, 
*P < 0.05, 1-way ANOVA. (b) Representative images of in vitro tube formation in control, 140uM glycine or 
20 ng/ml VEGF-treated ECs. Total sprouting length was indicated in the graph. Scale bar, 500 um (n = 5). (c) 
Representative images of the angiogenesis of saline, 140 uM glycine or 20 ng/ml VEGF-treated chorioallantoic 
membrane (CAM) (n = 6).
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Figure 3. Glycine obviously promoted the mitochondrial function. (a) FCCP coupled oxygen consumption rate 
(OCR) showing higher respiration in ECs treated with glycine than controls (n = 10). (b) Mitochondrial activity 
was tested by MTT in ECs treated with different amino acids (n = 12). (c) Intracellular ATP levels in control 
and glycine-treated ECs (n = 16). (d) Changes in mitochondrial membrane potential (ΔΨm) in ECs cultured 
in RPMI-1640 without amino acids medium or adding glycine. ΔΨm was indicated by Rh-123 fluorescence 
staining (λex = 460, λem = 520) and observed with a laser confocal microscope. Scale bar, 10 µm (n = 16). (e) 
Intracellular ROS levels in control and glycine-treated ECs as measured using DCFH-DA. ROS staining was 
observed with a laser confocal microscope. Left: representative images of ROS staining; right: ROS fluorescence 
intensity in per cell. Scale bar, 100 µm (n = 10). All values represented mean ± SEM of n independent 
experiments. **P < 0.01, *P < 0.05, 1-way ANOVA. (f) Intracellular NO levels in control, glycine or Ach-treated 
ECs as measured using DAF-FM DA. NO staining was observed with a laser confocal microscope. Upper: 
representative images of NO staining; Down: NO fluorescence intensity in per cell. Scale bar, 100 µm (n = 10). 
All values represented mean ± SEM of n independent experiments. **P < 0.01, *P < 0.05, 1-way ANOVA.
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Figure 4. VEGF activated GlyT1 and glycine directly bound to VDAC-1 on the mitochondria outer membrane. 
(a) Immunoblots of SHMT1 and SHMT2 in ECs treated with VEGF (n = 3). (b) The effects of sarcosine, an 
inhibitor of glycine transporter on the proliferation of ECs treated with VEGF (n = 12). (c) Immunoblots of 
GlyT1 and GlyT2 in ECs treated with VEGF (n = 3). (d) GlyT1 protein expression by Western blots in HUVECs 
electroporated with GlyT1 siRNA (si-GlyT1) or control siRNA (si-nc) treated with 20 ng/ml VEGF. (e) LC-MS 
was used to detect relative intracellular glycine in ECs with si-GlyT1 in the absence and presence of VEGF 
(n = 3). (f) VDAC1 was reconstituted in the plasma membrane of Hek-293A. The effects of glycine on single 
channel currents of VDAC-1 were recorded in +40 mV voltages using single channel patch-clamping (n = 7). 
(g) Statistical analysis of open probability (NPo) in the presence of Gd3 +(a VDAC1 inhibitor) and glycine 
(n = 7). All values represented mean ± SEM of n independent experiments. **P < 0.01, 1-way ANOVA.
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Materials and Methods
Cell culture. Human umbilical cords (UC) (n = 4 patients) were collected after a “written informed con-
sent” from all study subject participants with healthy full-term and naturally delivered newborns at the Peking 
University Third Hospital (Beijing) and the ethics was approved by University Ethics Committee, Institute of 
Molecular Medicine, Peking University. The experiments were performed in accordance with the guidelines on 
humane use and care of laboratory animals for biomedical research published by National Institutes of Health 
(No. 85-23, revised 1996). Human umbilical vein endothelial cells (HUVECs) were freshly isolated from umbili-
cal cord vein. HUVECs were grown in endothelial cell medium(Promocell) and maintained at 37 °C and 5% CO2. 
Experiments were conducted on cells before they reached the fifth passage. HEK-293A was purchased from Cell 
Library of Chinese Academy of Sciences and cultured (at 37 °C and 5% CO2) in the DMEM medium (Promocell, 
Germany) with 10% FBS (GIBCO, US).
Gd3+(Sigma), DCFH-DA (Sigma), rapamycin (Sigma), Sarcosine (Sigma), all amino acids (Sigma).
Immunoblotting. Cells were lysed ice-cold RIPA lysis buffer (Solarbio) including PMSF (Sigma) and pro-
teinase inhibitor cocktail (25x, Roche). Samples were centrifuged for 15 min at 12000 g at 4 °C and the superna-
tants were harvested. About 60ug of each protein sample were loaded and separated on 10% Bis-Tris Gel followed 
by transferring to 0.45 mm PVDF membrane. The membranes were then blocked with 5% non-fat dry milk, 
probed with appropriate primary antibodies, followed incubation by HRP-conjugated secondary antibodies at a 
dilution of 1: 5000. The following antibodies were used: rabbit anti-S6 Ribosomal Protein (5G10) (Cell Signaling, 
#2217), rabbit anti-Phospho-S6 Ribosomal Protein (Ser235/236) (Cell Signaling, #2211),, rabbit anti-mTOR 
(Proteintech, #20657-1-AP), rabbit anti-SHMT1 (Proteintech, #14149-1-AP), rabbit anti-SHMT2 (Proteintech, 
#11099-1-AP), mouse anti-ß-actin (Beijing TDY Biotech LTD, #M009), secondary HRP-conjugated anti-mouse 
and anti-rabbit antibodies (Beijing TDY Biotech LTD, #E009 and #E011 respectively).
Liquid chromatography–mass spectrometry (LC–MS). HUVECs were extracted with 1.5 ml of 4:1 v/v 
MeOH/H2O equilibrated at −80 °C. The extract and cells were scraped and collected into 2 ml EP tubes, held at 
4 °C for a further 5 min and centrifuged for 5 min at 12,000 g and solvent in the resulting supernatant was evap-
orated using a speed-vac. Samples were re-suspended in 30 μL HPLC-grade water for mass spectrometry. 8 μL 
were injected and analyzed using a 5500 QTRAP triple quadrupole mass spectrometer (AB/Sciex) coupled to a 
Prominence UFLC system (Shimadzu) via selected reaction monitoring (SRM) of 249. Some metabolites were 
targeted in both positive and negative ion mode for a total of 298 SRM transitions. ESI voltage was + 4900 V in 
positive ion mode and −4500V in negative ion mode. The dwell time was 5 ms per SRM transition and the total 
cycle time was 2.09 seconds. Approximately 8–10 data points were acquired for per detected metabolite.
Mouse model of hindlimb ischemia and evaluation of blood flow. Animal studies carried out in 
this study were approved and regulated by UK Government Home Office in accordance with the “Guidance on 
the operation of Animals” (Scientific Procedures) Act, 1986, in agreement with Aston University institutional 
guidelines and regulations for ethical animal use and care. All aspects of animal use and care took into account 
NC3RS (replacement, Reduction and Refinement) guidelines. The licensed protocols detailing the regulated 
animal procedures and care were carried out in accordance to the protocols section 19B of the Home Office 
licence as approved by UK Government Home Office in accordance with Scientific Procedures Act 1986 and 
Aston University Research Ethic Committee. Male C57BL/6 (Harlen) (22–26 g) were subjected to unilateral hind-
limb surgery under anesthesia with ketamine and Xyaline (100 mg/kg and 10 mg/kg respectively) as previously 
described32,33. The left femoral artery was separated from the vein and nerve, ligated proximally, and injected 
with 100 ul glycine with the concentration of 140 uM into the saphenous artery. Subsequently vein and artery 
was ligated and a small (1.5 mm secetion) of vein and artery was removed without effecting the nerve. Prior to 
tying the artery and vein off and remove. Glycine treatment was continoulsly provided 5% glycine in drinking 
water. The right hindlimb served as control. Blood flow was measured by Laser Doppler (Moor Instruments, UK). 
Plantar aspects of the non ischemic and ischemic feet of anesthetized mice (ketamine and Xyaline (100 mg/kg 
and 10 mg/kg respectively)was measured prior and post surgey in addition to days 3, 7 and 14 days post-surgery. 
Blood flow values were expressed as the ratio of ischemic to nonischemic hindlimb perfusion.
In vitro angiogenesis assay. HUVECs (1 × 104 cells/well) were seeded in 96 well plates coated with growth 
factor-reduced Matrigel (#356230, Corning). One hour after seeding, cells were stimulated with either 140 µM 
glycine or 20 ng/ml VEGF for 5 hours. Formation of capillary-like structures was observed using a Nikon inverted 
microscope. Images recording and analysis was performed by Image Pro-Plus image analysis software (Media 
Cybernetics).
Chorioallantoic angiogenesis membrane assay (CAM). Fertilized chicken eggs (purchased from 
China Agriculture University) were incubated for 6 days after breeding at 37 °C with 60% humidity. The method 
for preparing the CAM was described elsewhere with slight modification34. In general, eggs were cleaned with 
pre-warmed bromo-geramine and a small hole was drilled into the eggshell where the air sac is located. A 1 cm2 
window was carefully opened for inoculated. The small hole was then vacuumed to exclude air, thus creating 
space for the CAM. Gelatin sponge was soaked with 140 uM glycine or 20 ng/ml VEGF and seeded on the CAM. 
The window was then covered with parafilm and the egg was placed back into the incubator. Angiogenesis growth 
was observed daily. Five days after incubation, CAMs was removed, paraformaldehyde-fixed and observed.
Measurement of oxygen consumption. The Seahorse Bioscience Extracellular Flux Analyzer (XF24, 
Seahorse Bioscience Inc., North Billerica, MA, USA) was used to measure OCR (indicative of respiration). 
HUVECs were seeded (3–5 × 104) into 24 well plate. Appropriate growth media was added and incubated 
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overnight at at 37 °C and 5% O2. Cells were first washed and then immersed in unbuffered media prior to incu-
bation in CO2 depleted atmosphere for 1 h at at 37 °C. OCR was then measured using a Seahorse Bioscience 
Extracellular Flux Analyzer under the following parameters as recommended by Seahorse Bioscience guidelines; 
8-min cycle of mix (2–4 min), dwell (2 min) and measure (2–4 min).
Mitochondrial activity assay. For determination of mitochondrial activity, MTT assay was used as 
reported previously35. Briefly, HUVECs were seeded at a density of 2,000 per well into 96-well plates and left 
to adhere for 12 h. Subsequently, cells were treated with glycine for 5 h, MTT (5 mg/ml, Sigma) was added to 
each well for 2 h incubation. Aftewards, cells were collected, mixed in DMSO and absorbance measured at 
540 nm by Multiskan (Thermo). The relative mitochondrial activity was calculated by the absorbance ratio of the 
glycine-treated group to the control group.
ATP measurements. ATP was measured by the CellTiter-Glo® Luminescent Cell Viability Assay. Cells 
were aliquoted in a white microtitre plate (20,000 cells per well) in a 1:1 ratio with ATP Cell Titer-Glo® Reagent 
(Promega, Madison, WI, USA). The plate was incubated for 30 min at RT and luminescence was recorded.
Analysis of mitochondrial transmembrane potential (Δψm). Quantification of the mitochondrial 
transmembrane potential was conducted by LASER confocal microscope using the fluorescent probe Rhodamine 
123 (R302, Thermo Fisher) to demonstrate the state of mitochondrial transmembrane potential following the 
manufacturer’s protocol. Briefly, cells were starved with RPMI-1640 without amino acids medium for 50 min 
and then treat with glycine for 15 min. The cells were incubated with Rh123 (5 μg/ml) in a 37 °C incubator for 
20 minutes after washing twice with PBS. To measure specifically the mitochondrial membrane potential (ψm) we 
quantified the fluorescence intensity before and after applying FCCP, a mitochondrial electron chain uncoupler. 
The difference of intensity before and after applying FCCP corresponds specifically to the mitochondrial mem-
brane potential.
Intracellular reactive oxygen species measurement. Quantification of intracellular ROS was con-
ducted by LASER confocal microscope using the fluorescent probe, 2′,7′-dichlorodihydrofluorescein diacetate 
(DCFH-DA). HUVECs incubated with DCFH-DA (10 μM) in phenol red-free media supplemented for 20 min 
at 37 °C in the dark. Subsequently HUVECs were washed with PBS prior to quantification with laser confocal 
microscope.
Measurements of intracellular nitric oxide. Intracellular nitric oxide (NO) was quantified by laser con-
focal microscope using the fluorescent probe, DAF-FM DA (Beyotime, S0019). HUVECs were incubated in phe-
nol red-free media supplemented with 5 μM DAF-FM DA in dark for 20 min at 37 °C. They were then washed 
twice with PBS and immediately observed.
Electroporation. GlyT1 si-RNA was chemically synthesized and purified by high-performance liquid chro-
matography (GenePharma, Shanghai, China). The siRNA was transfected using the NeonTM transfection system 
according to the instructions. Medium 200 (Cat. no. M-200) supplemented with LSGS (Cat. no. S-003-10) was 
used. The electroporation parameters for HUVECs: pulse voltage was 1350 v; pulse width was 30ms and pulse 
number was 1.
Single channel recording. Conventional single channel of the patch-clamp technique was used in the 
electrophysiological study. Signals were amplified with an Axopatch 200B amplifier (Axon Instruments) and 
filtered at 1 kHz. Data acquisition and analysis were carried out using pClamp 9.0 (Axon Instruments) soft-
ware. The extracellular solution was composed of (in mM): 140 NaCl, 5 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 
and 23 sucrose (pH 7.4). The patch pipettes were made of borosilicate glass, and the pipette resistance was 4–6 
MΩ with the extracellular solution. We used the extracellular solution in the bath36. Single-channel activity was 
recorded at a pipette voltage of 40 mV. The data were acquired at 20 KHz and low-pass filtered at 5 kHz. During 
post-analysis, data were further filtered at 200 Hz. Single-channel events were listed and analysed by pclampfit 
9.0 (single-channel search-in-analyse function). NPo, the product of the number of channels and the open prob-
ability, was used to measure the channel activity within a patch. In total, 50% threshold cross-method was used 
to determine valid channel openings. Initial (1–2 min) single-channel records were normally used as the control. 
The activity of VDAC-1 during application of chemicals was normalized to activity during the control period to 
assess the effects of chemicals on VDAC-1 activity.
Statistical analysis. Analysis was conducted using either SPSS version 19.0 ((IBM SPSS, Armonk, NY, 
USA) or Graph Pad Prism (v7.0 USA). All values represent mean ± standard error of the mean. Significant dif-
ferences between the groups were determined were appropriate by either unpaired one-way analysis of variance 
test ANOVA or two-way analysis of variance test with repeated measures. A P-value P < 0.05 was considered to 
indicate statistical significant difference.
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